Dose-response relationships following oral administration of DuP 753 to normal humans by Christen, Y. et al.
AJH 1991; 4:350S-353S 
Dose-Response Relationships Following Oral 
Administration of DuP 753 to Normal Humans 
Y. Christen, B. Waeber, J. Nussberger, R.J. Lee, P.B.M.W.M. Timmermans, and H.R. Brunner 
W e assessed t h e i nh ib i t o ry effect of D u P 753, an or­
al ly act ive ang io tens in II receptor antagonis t , on t h e 
pressor act ion of exogenous ang io tens in I a n d II in 
h e a l t h y vo lun tee r s . In a s ingle dose s tudy, doses of 
2.5, 5,10, 20, a n d 40 m g of D u P 753 or p lacebo w e r e 
tes ted ser ia l ly at one w e e k in te rva ls . In t h e m u l t i p l e 
dose s tudy , t h e admin i s t r a t i on of p lacebo or D u P 
753 (5, 10, 20, or 40 mg, pe r os once daily) for e ight 
consecut ive days w a s eva lua ted . T h e b lood p re s su re 
r e sponse to ang io t ens in I a n d II w a s i n h i b i t e d in a 
dose -dependen t fash ion w i t h a b lock ing effect sti l l 
p re sen t 24 h post d rug . D u P 753 also i nduced a 
dose -dependen t compensa to ry r ise i n p l a s m a ren in . 
Th i s n e w c o m p o u n d w a s wel l to lera ted b y these 
n o r m a l vo lun tee r s . T h u s , D u P 753 appea r s to be a 
we l l tolerated, ora l ly active, po ten t a n d long- las t ing 
an tagonis t of ang io tens in II i n h u m a n s . A m J Hy­
pe r t ens 1991;4:350S-354S 
KEY WORDS : Ang io t ens in II, D u P 753, ang io tens in II 
an tagonis t . 
Saralasin (sar^ala 8 -angiotensin II) was the first receptor antagonist of angiotensin (ANG) II administered to h u m a n s . 1 - 3 This peptide an­tagonist was not orally active and had to be ad­
ministered parenterally. Therefore, long-term anti­
hypertensive t reatment was not possible. Furthermore, 
the antagonist was also a partial agonist . 4 Consequently, 
the majority of patients did not respond with a fall in 
blood pressure. 
Furukawa and his coworkers have synthetized some 
imidazole derivatives that specifically block the ANG 
II-induced vasoconstriction. 5 Important chemical modi­
fications of these initial molecules have led to the syn­
thesis of DuP 7 5 3 . 6 7 This compound is a potent antago­
nist of A N G II w h e n administered orally to animals . 8 ' 9 
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We have assessed for the first time the pharmacoki­
netic and pharmacodynamic profile of DuP 753 after 
single and repeated oral administration to normal 
h u m a n subjects. The results suggest that DuP 753 is a 
potent and long-acting antagonist of A N G II not only in 
animals, but also in h u m a n s . 1 0 
M E T H O D S 
A total of 37 male subjects aged 20 to 38 years were 
recruited to carry out the two consecutive studies. All 
subjects were considered heal thy on the basis of a medi­
cal history, a physical examination, a routine blood and 
urine analysis, and an electrocardiogram. The study 
protocols were approved by the institutional ethics 
committee. 
In order to quantitate the pressor effect of exogenous 
ANG, blood pressure was measured at the finger using a 
photople thysmograph (Finapres, Ohmeda , Englewood, 
CO). Throughout the studies, the volunteers were al­
lowed to continue their usual free sodium intake. They 
were asked to come to our research facility at 7 AM on 
the first day of the investigation after fasting over­
night. They were immediately placed in a supine posi­
tion and venous catheters were inserted in a vein in each 
forearm. 
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Study O n e (Single Dose Study) After a 30 min resting 
period to reach a steady baseline blood pressure and 
heart rate, a dose-response curve to bolus injections of 
A N G I was established. Angiotensin I (Senn Chemicals, 
Dielsdorf, Switzerland) was dissolved in 0.9% NaCl to 
achieve a concentration of 1 / / g /mL. The bolus injec­
tions were started at a dose of 10 n g / k g and increased 
thereafter every 10 to 15 min by steps of 10 n g / k g until a 
systolic blood pressure increase of 25 to 40 m m Hg was 
reached. This test dose was then repeated at least twice. 
The systolic blood pressure responses to these three con­
secutive injections of the test dose were averaged and 
the resulting mean used to define the baseline response 
to A N G I. 
DuP 753 is the potassium salt of 2-n-butyl-4-chloro-
5 - hy droxymethyl - l - [ (2 ' -4H - tetrazol - 5 - yl)biphenyl - 4 -
yl)methyl] imidazole (Ε. I. du Pont de Nemours & Com­
pany, Wilmington, DE) . 1 1 The dose to be administered 
was dissolved in 20 mL of tap water. The effect of the 
drug was then monitored using bolus injections of the 
ANG I test dose at times 15,30, and 45 min and 1, IV2,2, 
2 V 2 , 3 , 4 , 5 , 6 , 7 , 1 3 , 2 3 , 2 5 , and 27 (up to 33 for the 40 mg 
dose) h after drug intake. Between the hours 7 and 12 
and again between the hours 13 and 22, the subjects 
were allowed to leave the clinic. This two day protocol 
was repeated four times in each volunteer (except for 
one volunteer w h o only h a d 3 administrations) and at 
each phase a different dose of drug or placebo was given 
in single-blind fashion. 
Study T w o (Mul t ip le Dose Study) During the multi­
ple dose study, each subject received, in the mornings 
on 8 consecutive days, one dose of DuP 753 (either 5,10, 
20, or 40 mg) or placebo. Thus, each dose or placebo was 
given in single-blind fashion to six subjects, with the 
exception of the 20 mg dose, which was taken by only 
five volunteers. In this second investigation, A N G II 
was used as the agonist. Angiotensin II (Senn Chemi­
cals, Dielsdorf, Switzerland) was dissolved in 0.9% 
NaCl to achieve a concentration of 1 / /g /mL. The dose-
response curve to establish the test dose of ANG II was 
carried out during the week preceding the first adminis­
tration of DuP 753 using the same procedure described 
above. During study days 1 to 9, the subjects came every 
day at 8 AM and 8 PM to the research facility for measure­
ment of heart rate, weight, and blood pressure by a 
sphygmomanometer (sitting and standing). On study 
days 1 to 8, the dose of DuP 753 or placebo was admin­
istered at 8 AM in a similar fashion to the single-dose 
study. On days 1, 4, and 8, an ANG II challenge was 
performed before and again 6 and 12 h post-drug in­
take. Additional test doses were injected 24 h post drug 
on day 1 as well as 24, 30, and 36 h after the last dosing 
on day 8. 
Aldosterone was determined by a direct radioimmu­
noassay. 1 2 For the measurement of plasma renin activity 
(PRA), generated ANG I was t rapped and quanti tated 
by high affinity an t ibodies . 1 3 ' 1 4 For the quantitation of 
immunoreactive A N G II, a new method using monoclo­
nal antibodies against ANG II was u sed . 1 5 Norepineph­
rine was measured by a radioenzymatic a s say . 1 6 ' 1 7 Sub­
jects remained in a supine position for 30 min prior to 
blood sampling. 
The data are provided as mean ± SEM unless other­
wise indicated. They were evaluated with a one way 
ANOVA model. A Ρ < .05 was considered significant. 
The correlation coefficients were calculated, w h e n indi­
cated, by the method of least squares. 
RESULTS 
DuP 753 h a d no effect on resting blood pressure or pulse 
rate, neither after single administration nor during the 8 
day treatment. The compound was well tolerated and 
no clinically significant side effect was observed in ei­
ther of the two studies. Also, blood counts, the results of 
routine laboratory tests and urine analysis, and electro­
cardiogram measurements were not modified by DuP 
753. 
The changes in systolic blood pressure induced by the 
test dose of ANG I were calculated as the difference 
between post- and prechallenge values for each volun­
teer at each dose and at each time. Compared to placebo, 
no clear effect was observed with the doses of 2.5 and 
5 mg. Doses of 10, 20, and 40 mg induced however a 
dose-dependent inhibition of the response to A N G I. 
Figure 1 shows the dose-related inhibition of the re­
sponse to A N G I expressed in percent of the baseline 
response. The peak inhibitory effect was reached 7, 5, 
and 3 h after intake of the 10, 20, and 40 mg doses of 
DuP 753, respectively. 
Compared to placebo, the 8 day treatment with DuP 
753 taken once a day resulted in a dose-dependent re-
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FIGURE 1. Effect of single doses of oral DuP 753 (10, 20, or 40 
mg) or placebo on the systolic blood pressure (SBP) response 
(mean ± SEM) to test doses of ANG I in healthy volunteers. 
Adapted from Christen et al.10 
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auction in the systolic blood pressure response to ANG 
II throughout the treatment period. The degree of 
blockade achieved with the 20 and 40 mg doses was 
similar 6 h post-drug intake on days 1,4, and 8 (P < .01 
for effect of DuP 753 ν placebo). On days 4 and 8, 
however, the subjects receiving 40 mg of DuP 753 
showed a clear t rend towards a reduced response to 
exogenous A N G II immediately before the morning 
dose of the drug (Figure 2). 
Plasma aldosterone levels fell after administration of 
single doses of DuP 753, but a similar decrease was also 
seen after placebo. The single doses of DuP 753 pro­
duced a dose dependent increase in plasma A N G II, 
while no change was observed after placebo administra­
tion. As early as 30 min after the highest dose of 40 mg, 
a small rise was already apparent . N o significant change 
in plasma norepinephrine was observed after single ad­
ministration of DuP 753. 
Figure 3 depicts the PRA and plasma ANG II levels 
measured at the beginning and at the end of repeated 
administration of placebo or DuP 753. Both PRA and 
A N G II showed a marked dose-dependent increase 6 h 
post-drug intake, and this rise was clearly more pro­
nounced on day 8 than on day 1. Both variables had 
already increased significantly 6 h after 20 mg of DuP 
753 on the first day, (P < .05 ν placebo). While the base­
line results on day 1 were all very similar, on day 8 there 
was a t rend for a dose-dependent increase even of the 
pre-drug values. 
DISCUSSION 
These data demonstrate that DuP 753 is a potent orally 
active A N G II antagonist with a relatively long duration 
of action. At peak effect, the 40 mg dose induced an 
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FIGURE 2. Effect of eight consecutive days of treatment with 
daily oral doses of DuP 753 (10, 20, or 40 mg) or placebo on the 
systolic blood pressure (SBP) response (mean ± SEM) to test doses 
of ANG II in healthy volunteers. Adapted from Christen et al.10 
MULTIPLE DOSE STUDY 
1 0 
ξ 8 










P r e - d r u g 6 h p o s t — d r u g 
DAY 1 
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FIGURE 3. Effect of different doses of daily oral DuP 753 (10, 
20, or 40 mg) or placebo (n = 6 for each dose except the dose of 20 
mg where n = 5) on plasma renin activity and immunoreactive 
ANG II measured before and 6 h post-drug intake on days 1 and 8. 
Values are given as mean ± SEM. *P < .05 ν placebo. Adapted 
from Christen et al.10 
approximately 70% reduction in the systolic pressure 
response to A N G I or II. With this highest dose, even 
24 h post-drug a definite effect was still present. Plasma 
renin activity and ANG II levels also responded with a 
dose-dependent compensatory rise as one might have 
expected based on earlier observations made with sara­
lasin, 2 as well as on the extensive experience accumu­
lated with angiotensin converting enzyme (ACE) inhibi­
tors. This compensatory rise was dose-dependent and 
more pronounced on day 8 of drug administration than 
on day 1. This also is in agreement with findings ob­
tained after administration of ACE inhibi tors . 1 8 The 
long duration of the blocking effect of DuP 753 is also 
reflected in the plasma renin activity and A N G II levels. 
Thus, while on day 1 all predrug measurements pro­
vided similar results, on day 8, plasma renin activity as 
well as plasma A N G II were clearly increased before the 
administration of 20 and 40 mg as compared to the 
pre-drug results obtained before placebo. 
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N o significant effect of the ANG II antagonist on 
plasma aldosterone could be detected. There are m a n y 
possible reasons w h y there was no net effect of the drug 
on plasma aldosterone. Most importantly, the 40 mg 
dose did not provide maximal receptor blockade at the 
vascular receptors. It is also conceivable that the re­
peated bolus injections of ANG I or II in the face of 
incomplete receptor blockade may have exerted a stimu­
lating effect on aldosterone secretion. 
The clinically most relevant question is of course h o w 
DuP 753 as a therapeutic agent compares to the various 
agents already available for blockade of the renin-an­
giotensin cascade. Obviously, the present s tudy cannot 
provide any conclusive answer to this question since the 
drug was administered only to normal volunteers. Nev­
ertheless, it is already evident that this A N G II antago­
nist exhibits features which appear particularly promis­
ing as a future therapeutic agent. Compared to saralasin 
it has the evident and decisive advantage of being orally 
active. Furthermore, while the present data cannot rule 
out the existence of an agonistic effect of D u P 753 be­
cause relatively small doses were administered, it seems 
likely that no such effect will occur in humans , since in 
various animal studies none was observed at very high 
doses of d rug . 7 These preliminary data obtained in nor­
mal volunteers do not allow us to predict the antihyper­
tensive potency and efficacy of D u P 753. Nevertheless, 
the findings obtained with D u P 753 in hypertensive 
animals and the earlier observations made with sarala­
sin suggest that DuP 753 will likely become an effective 
compound to treat hypertension and possibly conges­
tive heart failure. Compared to angiotensin converting 
enzyme inhibitors, it would have the advantage of 
greater specificity. It shares with the ACE inhibitors, as 
well as with the renin inhibitors, the unescapable fact 
that the closed regulatory loop of renin secretion is fully 
operative, and as a consequence, blockade at any point 
beyond the renin secreting process automatically in­
duces a compensatory rise in renin and A N G II. 
Whether this compensatory rise has any clinical conse­
quences remains to be seen. 
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